Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Biologists develop a novel treatment for all SARS-CoV-2 variants
Scientists are currently testing mice infected with SARS-CoV-2.
LongHR2 42, a substance developed by biologists from the International Biophysical Society, has been shown to suppress all variants of SARS-CoV-2. The researchers used a portion of the coronavirus envelope's S-protein. The findings of the scientists have been published in the journal PNAS.
"The S-protein molecules in viable coronavirus particles are divided into two parts, one short and one long, which together form the complex required for virus entry into cells. We created a short molecule analogue that penetrates the S-protein(a spiky outgrowth on the surface of the virus membrane) and prevents the virus from infecting cells "Stanford University Professor Axel Brunger stated.
The new drug targets the heptad potentate HR1HR2, a protein that plays an important role in virus penetration into human cells. The drug causes HR1HR2 to fuse with a scientifically modified version of the HR2 peptide, inhibiting pathogen reproduction in the body.
Furthermore, because HR1HR2 remains nearly unchanged as SARS-CoV-2 evolves, drugs targeting it are effective against all strains of the pathogen, including Omicron.
Scientists are currently testing mice infected with SARS-CoV-2. Inhalation applications of the drug are expected in the near future to help avoid severe respiratory symptoms.